CD8A and neoplasm: Additionally, using a preclinical mouse model of NSCLC known as 344SQ, treatment with MRX34 led to a decreased expression of PD-L1 protein, increased infiltration of tumor-fighting CD8+ cells, and decreased infiltration of PD1+ T-cells, macrophages, and T-regulatory cells, leading to delay in tumor growth [157].